pmid,title,journal,year,drug,disease
40794751,Non-negligible risk of HBV reactivation among rheumatoid arthritis patients receiving JAK inhibitors: bridging the evidence gap.,"Rheumatology (Oxford, England)",2025,Baricitinib,Hepatitis B
39014279,Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review.,Dermatology and therapy,2024,Baricitinib,Hepatitis B
37084117,Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19.,European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,2023,Baricitinib,Hepatitis B
36794347,Hepatitis B virus reactivation associated with Janus kinase (JAK) inhibitors: a retrospective study of pharmacovigilance databases and review of the literature.,Expert opinion on drug safety,2023,Baricitinib,Hepatitis B
36695072,Expert consensus on the systemic treatment of atopic dermatitis in special populations.,Journal of the European Academy of Dermatology and Venereology : JEADV,2023,Baricitinib,Hepatitis B
35235148,Management of hepatitis B virus reactivation due to treatment of COVID-19.,Hepatology international,2022,Baricitinib,Hepatitis B
33510353,Network theoretic analysis of JAK/STAT pathway and extrapolation to drugs and viruses including COVID-19.,Scientific reports,2021,Baricitinib,Hepatitis B
32098857,Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.,RMD open,2020,Baricitinib,Hepatitis B
